Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA.
Intermountain Healthcare & University of Utah School of Medicine, Salt Lake City, UT 84107, USA.
Future Cardiol. 2021 Oct;17(7):1277-1291. doi: 10.2217/fca-2020-0188. Epub 2021 Mar 19.
SARS-CoV-2 is responsible for the 2020 global COVID-19 pandemic. In patients with COVID-19, multiple cardiovascular (CV) manifestations have been reported. SARS coronavirus 2 infection can lead to inflammatory CV disease first via takeover of the angiotensin-converting enzyme-2 enzyme as a cell receptor as well as the macrophage activation syndrome in severe illness. We review the CV manifestations of COVID-19 and therapeutics under investigation. We discuss the potential long-term CV sequelae after recovery from COVID-19 and the gaps in knowledge including the pathophysiological links between acute cardiac injury, myocardial inflammation and chronic cardiomyopathy. Future investigational efforts could result in significant diagnostic and therapeutic advances potentially impacting the broader field of chronic heart failure and cardiac recovery.
SARS-CoV-2 是 2020 年全球 COVID-19 大流行的罪魁祸首。在 COVID-19 患者中，已经报道了多种心血管（CV）表现。SARS 冠状病毒 2 感染可导致炎症性 CV 疾病，首先是通过接管血管紧张素转换酶-2 酶作为细胞受体以及重症疾病中的巨噬细胞活化综合征。我们回顾了 COVID-19 的 CV 表现和正在研究的治疗方法。我们讨论了 COVID-19 康复后潜在的长期 CV 后遗症，以及包括急性心脏损伤、心肌炎症和慢性心肌病之间的病理生理联系在内的知识空白。未来的研究工作可能会带来重大的诊断和治疗进展，可能会对慢性心力衰竭和心脏康复的更广泛领域产生影响。
